knowledge -WSS

knowledge

author：fashion 2025-08-31 16:39:17 - browse：57788

Erik Tokat -- biotech JPM coverage from STAT — Eric Tokat is co-president of investment banking at Centerview Partners. Courtesy Centerview Partners

SAN FRANCISCO — Eric Tokat, biotech’s most prolific dealmaker, believes 2024 will be another strong year for acquisitions, driven by Big Pharma’s need to restock pipelines with medicines that can generate sales in the coming years.

That’s not idle speculation. It’s perhaps as close to a guarantee one can get in biotech. Last year, Tokat’s advisory firm, Centerview Partners, was involved in 19 of the 23 biotech transactions valued at $1 billion or more. Two more acquisitions of Centerview clients — Harpoon Therapeutics and Ambrx Biopharma — were announced Monday morning.

“I’m not sure if we’re going to have 23 deals or 25 deals, but I think it’s going to be a good year,” said Tokat, speaking to STAT over coffee on the sidelines of the J.P. Morgan Healthcare Conference.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： Eyeing GLP

WSS

Bird flu surveillance in wastewater gets boost from consortium

The Readout: Biogen, Guardant, AstraZeneca, H5N1 vaccine

Stories you might have missed in 2023: health, science, medicine

Readout Newsletter: Eli Lilly, AstraZeneca, Bristol Meyers Squibb

FDA early review: GLP

Liver decline slowed by off

hotspot

knowledge

focus

23andMe had bad news about my health. I wish a person had delivered it

Hospital chaplains balance Covid safety with patients’ spiritual needs

Continuity nursing helped my family in our darkest PICU moments

Digital health: a case of mistaken identity

23andMe had bad news about my health. I wish a person had delivered it

For longer

State Dept. review finds Biden bears some blame for Afghanistan failures

As a primary care physician, here's how I hope to partner with AI

DIEP, the 'gold standard' of breast reconstruction, is under threat

Medicare Advantage coverage denials need scrutiny, senators say

focus

ASCO eve: Let’s set the table for this year's meeting

UnitedHealth argues against case alleging wrongful AI care denials

Medicare Advantage overpayments discussion gets experts fired up

Scrutiny of post

Medicare Advantage coverage denials need scrutiny, senators say

Boston Scientific acquires urology company Axonics for $3.7 billion

leisure time

knowledge

Wikipedia

explore